

Program of Events

SOHO 2018

WEDNESDAY, SEPTEMBER 12, 2018

DATE/TIME	TOPIC/EVENT	SPEAKER	AFFILIATION
BREAKFAST WITH THE EXPERT I			
7:00 AM	CML: From the Bench to Bedside	Jerald P. Radich, MD	University of Washington School of Medicine Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
BREAKFAST WITH THE EXPERT II			
7:00 AM	Clonal Hematopoiesis and Pre-Leukemia	David P. Steensma, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
MEET-THE-PROFESSOR SESSIONS			
8:00 AM	MTP Session I: CML Session Chair: Timothy Hughes		Level 3, 339AB
	New Drugs, New Options	Jorge Cortés, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Case Studies: Approach to Resistance	Jane F. Apperley, MBChB, MD, FRCP, FRCPATH	Hammersmith Hospital London Imperial College, London, UK
	Treatment Free Remission: Selecting The Best Candidates	Agnes S. M. Yong, MD, PhD	South Australian Health and Medical Research Institute, Adelaide, Australia
8:00 AM	MTP Session II: ALL Session Chair: Wendy Stock		Level 3, 346AB
	Approach to Ph-like ALL	Sarah K. Tasian, MD	Children's Hospital, Pennsylvania, Philadelphia, USA
	How I Treat the Relapsed Patient	Wendy Stock, MD	The University of Chicago, Chicago, Illinois, USA
	Management and Prevention of CAR-T Toxicities	Bijal D. Shah, MD	H. Lee Moffitt Cancer Center, Tampa, Florida, USA
8:00 AM	MTP Session III: AML Session Chair: Elihu Estey		Level 3, 340AB
	Quantifying Potential Selection Bias in AML Clinical Trials	Elihu H. Estey, MD	Fred Hutchinson Cancer Research Center , University of Washington School of Medicine, Seattle, Washington, USA
	FLT3 Inhibitors in AML	Alexander E. Perl, MD	University of Pennsylvania, Philadelphia, Pennsylvania, USA
	BCL-2 Inhibition in AML	Marina Y. Konopleva, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	IDH Inhibitors in AML	Courtney D. DiNardo, MD, MSCE	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM	MTP Session IV: MPN Session Chair: Laura Michaelis		Level 3, 337AB
	Managing MF Patients After Ruxolitinib Failure	Robyn M. Scherber, MD	Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, Texas, USA
	Managing PV Patients After Hydroxyurea Failure	Abdulraheem Yacoub, MD	University of Kansas Medical Center, Kansas City, Kansas, USA
	Managing ET Patients After Hydroxyurea Failure	Laura C. Michaelis, MD	Medical College of Wisconsin, Milwaukee, Wisconsin, USA
8:00 AM	MTP Session V: NHL Session Chair: Simon Rule		Level 3, 336AB
	Mantle Cell Lymphoma	Simon Rule, MD	Derriford Hospital, Plymouth, United Kingdom
	R-Chemotherapy in the Era Biosimilars	Bertrand Coiffier, MD, PhD	Centre Hospitalier Lyon-Sud, Lyon, France
	CAR T Cells For Lymphoma: Efficacy And Managing Toxicity	Sattva Neelapu, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM	MTP Session VI: MDS Session Chair: David Steensma		Level 3, 338
	Treatment of Lower Risk MDS	David P. Steensma, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
	Treatment of Higher Risk MDS	Hetty E. Carraway, MD, MBA	Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
	Treatment of Relapsed MDS	Rami Komrokji, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

8:00 AM	MTP Session VII: CLL Session Chair: William Wierda		Level 3, 344AB
	CAR-T	William Wierda, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	The Application of CAR-NK Cell Therapy in CLL	Katy Rezvani, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Allo SCT	Mauricette Michallet, MD, PhD	Centre Hospitalier Lyon-Sud, Lyon, France
8:00 AM	MTP Session VIII: Research Session Chair: Helen Heslop		Level 3, 327
	Immune Checkpoint Blockade: Present and Future	Madhav V. Dhodapkar, MBBS	Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
	Antibody Therapy for Lymphoma	Jonathon B. Cohen, MD, MS	Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
	Cell Therapy of Hematologic Diseases	Helen E Heslop, MD, DSc (Hon)	Baylor College of Medicine, Houston, Texas, USA
8:00 AM	MTP Session IX: Advanced Oncology Nurse Session Chair: Mary Beth Rios		Level 3, 328
	Immunology in Hematologic Oncology	Sherry A. Adkins, RN, MSN, ANP-C	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Early Assessment and Support of Hematologic Oncology Patients Receiving Living Immune Effector Cell Therapies	Joaquin A. Buitrago, MS, RN, OCN	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM	MTP Session X: Hematopathology Session Chair: Carlos Bueso-Ramos		Level 3, 329
	Advances in the Pathology of Myelodysplastic Syndromes	Rashmi Kanagal-Shamanna, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Advances in the Pathology of Acute Myeloid Leukemia	Carlos E. Bueso-Ramos, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:15 AM	BREAK		
SESSION I: CHRONIC MYELOID LEUKEMIA			
Session Chairs: Jerald Radich and Delphine Rea			
9:30 AM	Welcome and Announcements	Alan F. List, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
9:40 AM	CML: State of the Art Update	Jorge Cortés, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:55 AM	ELN v NCCN: Do We Have Consensus?	Charles A. Schiffer, MD	Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
10:10 AM	Case Studies in TFR	Delphine Rea, MD, PhD	Saint Louis Hospital, Paris, France
10:25 AM	When Second Generation TKIs Fail	Jerald P. Radich, MD	University of Washington School of Medicine Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
10:40 AM	DEBATE : Second Generation TKIs are the Preferred Frontline Treatment Option for All CML Patients Where TFR is the Main Goal - Pro	Giuseppe Saglio, MD	The University of Turin and San Luigi Hospital, Turin, Italy
10:55 AM	DEBATE : Second Generation TKIs are the Preferred Frontline Treatment Option for All CML Patients Where TFR is the Main Goal - Con	Jane F. Apperley, MBChB, MD, FRCP, FRCPath	Hammersmith Hospital London Imperial College, London, United Kingdom
11:10 AM	Advanced Phase Disease: Current Management	Michael Deininger, MD, PhD	Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
11:25 AM	Oral Abstract Presentations CML-044: Treatment-Free Remission (TFR) in Patients With Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib	Michael J. Mauro, MD, PhD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
11:35 AM	CML-057: ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib	Timothy P. Hughes, MD, FRACP, FRCPA	South Australian Health and Medical Research Institute, Adelaide, Australia
11:45 AM	CML: Next Questions	Timothy P. Hughes, MD, FRACP, FRCPA	South Australian Health and Medical Research Institute, Adelaide, Australia
INDUSTRY EXPERT SESSION			
12:00 PM	Industry Expert Lunch Session Treatment Considerations in Polycythemia Vera and Myelofibrosis: A Clinical Update <i>This activity is supported by Incyte</i>	Ellen Ritchie, MD	Weill Cornell Medical College, New York, New York, USA

PLENARY SESSION I

Session Chair: Ching-Hon Pui

1:30 PM	<i>Keynote Speaker</i> : Update on AYA ALL: Progress, Challenges and Next Steps Recipient of the SOHO 2018 Distinguished Lecturer Award	Wendy Stock, MD	The University of Chicago, Chicago, Illinois, USA
---------	--	-----------------	---

SESSION II: MYELOYDYSPLASTIC SYNDROMES

Session Chairs: Valeria Santini and Lucy Godley

1:50 PM	What is New in MDS in 2018?	Valeria Santini, MD	University of Florence, Florence, Italy
2:05 PM	Selecting the Right Lower Risk Patient for Stem Cell Transplantation	Uwe Platzbecker, MD	University Hospital Carl Gustav Carus, Dresden, Germany
2:20 PM	Inherited Predisposition and Pediatric MDS	Marcin W. Wlodarski, MD, PhD	St. Jude Children's Hospital, Memphis, Tennessee, USA
2:35 PM	BREAK		
3:05 PM	Debate : Should MDS Diagnosis Still Be Mainly Based on Morphology? Yes	Robert Paul Hasserjian, MD	Massachusetts General Hospital, Boston, Massachusetts, USA
3:20 PM	Debate : Should MDS Diagnosis Still Be Mainly Based on Morphology? No	Lucy A. Godley, MD, PhD	The University of Chicago, Chicago, Illinois, USA
3:35 PM	Improving Results with Hypomethylating Agents in MDS	Pierre Fenaux, MD, PhD	Hospital St. Louis, Paris, France
	Oral Abstract Presentations		
3:50 PM	MDS 161 : Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)	Yazan F. Madanat, MD	Taussig Cancer Institute, Cleveland, Ohio, USA
4:00 PM	MDS 304 : Mutational Landscape of Therapy-Related Myeloid Neoplasms	Teodora Kuzmanovic, BA	Taussig Cancer Institute, Cleveland, Ohio, USA
4:10 PM	Problems Ahead in MDS: What is Next?	Guillermo Garcia-Manero, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

SESSION III: MYELOPROLIFERATIVE NEOPLASMS

Session Chairs: Srdan Verstovsek and Radek Skoda

4:25 PM	State of the Art Update: The Origins of MPN	Radek C. Skoda, MD	University Hospital Basel, Basel, Switzerland
4:40 PM	Assessing Thrombotic Risk of ET and PV in the Genomic Era	Laura C. Michaelis, MD	Medical College of Wisconsin, Milwaukee, Wisconsin, USA
4:55 PM	Rare Malignancy Topic: Primer on Advanced Mastocytosis	Robyn M. Scherber, MD	Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, Texas, USA
5:10 PM	Will Mutations Affect Transplant Decisions in Myelofibrosis	H. Joachim Deeg, MD	Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA
5:25 PM	Case Study: Accelerated MF	Srdan Verstovsek, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5:40 PM	Next Questions: Understanding Fibrotic and Leukemic Transformation of MPN	Radek C. Skoda, MD	University Hospital Basel, Basel, Switzerland
	Oral Abstract Presentations		
5:55 PM	MPN 136 : When Two Roads Diverge: Genetically Inspired Prognostic Scoring System (GIPSS) Outperforms DIPSS in Myelofibrosis Patients Where the Two Risk Models Widely Differ	Andrew Kuykendall, MD	H. Lee Moffitt Cancer Center, Tampa, Florida, USA
6:05 PM	MPN 285 : Genomic Landscape and Clinical Features of Triple-Negative Myelofibrosis	Kristen M. Pettit, MD	University of Michigan, Ann Arbor, Michigan, USA
6:15 PM	ADJOURN		
6:15 PM	POSTER SESSION		
6:15 PM	WELCOME RECEPTION AND AWARDS		

THURSDAY, SEPTEMBER 13, 2018

DATE/TIME TOPIC/EVENT SPEAKER AFFILIATION

INDEPENDENT SATELLITE SYMPOSIUM (ISS)

6:30 AM	ISS Registration and Breakfast		
7:00 AM	Independent Satellite Symposium Evolving Paradigms in AML: Navigating New Therapeutic Opportunities in the Frontline and Relapsed Settings Farhad Ravandi, MD; Naval Daver, MD; Guillermo Garcia-Manero, MD; Richard Stone, MD <i>This CME activity is provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Daiichi Sankyo, Inc., Helsinn, and Jazz Pharmaceuticals</i> For more information and to register for this independent symposium, go to www.managingaml.com/evolving		

BREAKFAST WITH THE EXPERT IV

7:00 AM Molecular Genetics of MDS Torsten Haferlach, MD, PhD MLL Munich Leukemia Laboratory, Munich, Germany

SESSION IV: ACUTE LYMPHOBLASTIC LEUKEMIA

Session Chairs: Wendy Stock and Nicola Gökbüget

8:00 AM Welcome and Announcements

8:05 AM ALL: State of the Art Update Nicola Gökbüget, MD Goethe University Hospital, Frankfurt, Germany

8:20 AM CART T Cell Therapy: CD19, CD22 and Beyond Terry J. Fry, MD Children's Hospital Colorado, Aurora, Colorado, USA

8:35 AM MLL Leukemias: A Remaining Hurdle Rob Pieters, MD, PhD Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

8:50 AM Combining Molecular Genetics and Cytogenetics for Prognostication Hervé Dombret, MD Institut Universitaire d'Hématologie, Paris, France

9:05 AM Autoimmunity Checkpoints In B-cell Lineage ALL Markus Müschen, MD, PhD City of Hope, Duarte, California, USA

9:20 AM Can MRD Monitoring Be Done Using Peripheral Blood? Lori Muffly, MD Stanford University Medical Center, Palo Alto, California, USA

9:35 AM T-ALL: Nelarabine In The Frontline; and What to Do About Relapse? Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Oral Abstract Presentations

9:50 AM **ALL 114:** Characterization of PAX5 -Driven Subtypes in B-Progenitor Acute Lymphoblastic Leukemia Zhaohui Gu, PhD St. Jude Children's Research Hospital, Memphis, Tennessee, USA

10:00 AM **ALL 131:** Safety and Efficacy of the BCL Inhibitors Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Andrew Hantel, MD University of Chicago, Chicago, Illinois, USA

10:10 AM ALL: Next Questions Nicola Gökbüget, MD Goethe University Hospital, Frankfurt, Germany

10:25 AM **BREAK**

SESSION V: ACUTE MYELOID LEUKEMIA

Session Chairs: Richard Stone and Alan Burnett

10:55 AM AML: State of the Art Update Harry P. Erba, MD, PhD Duke University, Durham, North Carolina, USA

11:10 AM NGS at Diagnosis: Uses And Pitfalls Christopher James Gibson, MD Dana-Farber Cancer Institute, Boston, Massachusetts, USA

11:25 AM Induction: Should We "GO" To FLAG-ida, etc? Alan K. Burnett, MD Formerly Cardiff University School of Medicine, Cardiff, United Kingdom

11:40 AM MRD: Is it a Thing in AML? Gert Ossenkoppele, MD, PhD VU University Medical Center, Amsterdam, The Netherlands

11:55 AM Immunotherapy in AML: Anything There? Naval G. Daver, MD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

12:10 PM CAR-transduced T and NK cells In AML: Near or Far Away Katy Rezvani, MD, PhD The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

12:25 PM **Debate:** Use Gemtuzumab in Most AML Patients vs Use Gemtuzumab in CBF Patients or Not at All? **Pro** Roland B. Walter, MD, PhD Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA

12:40 PM **Debate:** Use Gemtuzumab in Most AML Patients vs Use Gemtuzumab in CBF Patients or Not at All? **Con** Gail J. Roboz, MD Weill Medical College of Cornell University, New York, New York, USA

Oral Abstract Presentations

12:55 PM **AML 129:** Durable Response with Venetoclax in Combination with Decitabine or Azacitadine in Elderly Patients with Acute Myeloid Leukemia (AML) Courtney D. DiNardo, MD, MSCE The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

1:05 PM **AML 152:** Hypomethylating Agents Versus Intensive Chemotherapy in Older Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count Chetasi Talati, MD H. Lee Moffitt Cancer Center, Tampa, Florida, USA

1:15 PM **SCT 020:** Incidence, Risk Factors and Treatment Response in Patients with Chronic Graft Versus-Host Disease After Haploidentical Transplantation with Post-Transplantation Cyclophosphamide Daniel Rivera, MD Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain

1:25 PM	AML: Next Questions	Richard Stone, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
---------	---------------------	-------------------	--

INDUSTRY EXPERT SESSION

1:40 PM	Industry Expert Lunch Session Discover the Role of Two Immunotherapies in Myeloma Treatment <i>This activity is supported by Celgene</i>	William I. Bensinger, MD	Swedish Cancer Institute, Seattle, Washington, USA
---------	---	--------------------------	--

PLENARY SESSION II

Session Chair: Hagop Kantarjian

3:10 PM	One Treatment For All in ALL: A Stratified Treatment Approach for Patients 1-45 Years Old	Kjeld Schmiegelow, MD	Copenhagen University Hospital, Copenhagen, Denmark
---------	---	-----------------------	---

SESSION VI: MULTIPLE MYELOMA

Session Chairs: Sagar Lonial and Sundar Jagannath

3:30 PM	MM: State of the Art Update	Sagar Lonial, MD, FACP	Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
---------	-----------------------------	------------------------	---

3:45 PM	How Does Genetics and MRD Impact Treatment or Doesn't It?	Ajay K. Nooka, MD, MPH, FACP	Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
---------	---	------------------------------	---

4:00 PM	New Targets in Relapsed And Refractory MM	Thomas G. Martin, MD	University of California San Francisco, San Francisco, California, USA
---------	---	----------------------	--

4:15 PM	Management and Diagnosis of Amyloid: What is New?	Suzanne Lentzsch, MD, PhD	Columbia University and at New York Presbyterian Hospital, New York, USA
---------	---	---------------------------	--

4:30 PM	Emerging Data on Management and Imaging of Myeloma Bone Disease	Meletios Dimopoulos, MD	University of Athens, Athens, Greece
---------	---	-------------------------	--------------------------------------

4:45 PM BREAK

5:15 PM	What Will the Future Hold for Myeloma Treatment CARTs vs BITES?	Robert Z. Orlowski, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
---------	---	-----------------------------	--

5:30 PM	The Role of ASCT in the Era of Modern MM Therapy	Peter M. Voorhees, MD	Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
---------	--	-----------------------	--

Oral Abstract Presentations

5:45 PM	MM 107: Overall Survival of Patients Post-Transplant: Study Results From Two Phase 3 Trials ASPIRE and ENDEAVOR	Rafat Abonour, MD	Indiana Cancer Pavilion, Indianapolis, Indiana, USA
---------	--	-------------------	---

5:55 PM	MM 205: Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM)	Sundar Jagannath, MD	Icahn School of Medicine at Mount Sinai, New York, New York, USA
---------	--	----------------------	--

6:05 PM	MM: Next Questions	Sundar Jagannath, MD	Icahn School of Medicine at Mount Sinai, New York, New York, USA
---------	--------------------	----------------------	--

6:20 PM ADJOURN

INDUSTRY EXPERT SESSION

6:20 PM	Industry Expert Dinner Session IMBRUVICA® with a focus on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Ryan Jacobs, MD Levine Cancer Institute/Carolinas Healthcare System/UNC-Chapel Hill School of Medicine Michael Schuster, MD Stony Brook University <i>This activity is supported by Pharmacyclics and Janssen</i>		
---------	--	--	--

FRIDAY, SEPTEMBER 14, 2018

DATE/TIME	TOPIC/EVENT	SPEAKER	AFFILIATION
-----------	-------------	---------	-------------

INDEPENDENT SATELLITE SYMPOSIUM (ISS)

6:00 AM	ISS Registration and Breakfast		
6:30 AM	Independent Satellite Symposium Personalized Treatment for High-Risk and FLT3+ Relapsed or Refractory AML Alexander E. Perl, MD; Naval Daver, MD; Amir T. Fathi, MD <i>This CME activity is provided by Haymarket Medical Education. This activity is supported by an educational grant from Astellas Pharma US, Inc. For more information and to register for this independent symposium, go to mycme.com/AML2018</i>		

BREAKFAST WITH THE EXPERT V

7:00 AM	Follicular Lymphoma	Robert Marcus, MA, FRCP, FRCPATH	Leaders in Oncology Care, London, United Kingdom
---------	---------------------	----------------------------------	--

SESSION VII: HODGKIN LYMPHOMA

Session Chairs: David Straus and Stephen Ansell

8:00 AM	Treatment of Newly Diagnosed HL	David J. Straus, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
---------	---------------------------------	---------------------	---

8:15 AM	Treatment of Relapsed HL	Stephen M. Ansell, MD, PhD	Mayo Clinic, Rochester, Minnesota, USA
---------	--------------------------	----------------------------	--

8:30 AM	<p>Oral Abstract Presentation HL 156: Impact of Imaging Modality on Clinical Outcome in Hodgkin Lymphoma in a Resource Constrained Setting</p>	Anu Korula, MD, DM	Christian Medical College, Vellore, India
SESSION VIII: NON-HODGKIN LYMPHOMA			
Session Chairs: Anas Younes and Simon Rule			
8:40 AM	Biology of DLBCL	Laura Pasqualucci, MD	Columbia University, New York, New York, USA
8:55 AM	Treatment of Newly Diagnosed DLBCL	Catherine Thieblemont, MD, PhD	Hôpital Saint Louis, Paris, France
9:10 AM	Treatment of Relapsed DLBCL	Thomas E. Witzig, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
9:25 AM	Marginal Zone Lymphoma	Emanuele Zucca, MD	Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
9:40 AM	Biology of T-Cell Lymphoma	Laurence de Leval, MD, PhD	University Hospital of Lausanne, Switzerland
9:55 AM	Treatment of Newly Diagnosed and Relapsed T-Cell Lymphoma	Steven M. Horwitz, MD, PhD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
10:10 AM	BREAK		
10:40 AM	New Approaches to the Management of CTCL	Pierluigi Porcu, MD	Jefferson Hospital, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, USA
10:55 AM	Mantle Cell Lymphoma Biology	Elías Campo, MD	Hospital Clinic of the University of Barcelona, Barcelona, Spain
11:10 AM	Management of Newly Diagnosed MCL	Simon Rule, MD	Derriford Hospital, Plymouth, United Kingdom
11:25 AM	Management of Relapsed MCL	Luhua M. Wang, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
INDUSTRY EXPERT SESSION			
11:40 AM	<p>Industry Expert Lunch Session An Oral Option for the Treatment of B-Cell Malignancies: A Case Study Review <i>This activity is supported by Gilead</i></p>	Michael W. Schuster, MD	Stony Brook University, Stony Brook, New York, USA
PLENARY SESSION III			
Session Chair: Nathan Fowler			
1:10 PM	Precision Medicine in Lymphoma	Anas Younes, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
(..cont) SESSION VIII: NON-HODGKIN LYMPHOMA			
1:30 PM	Biology of Follicular Lymphoma	Hans-Guido Wendel, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
1:45 PM	Management of Newly Diagnosed FL	Mathias J. Rummel, MD, PhD	Justus-Liebig University-Hospital, Giessen, Germany
2:00 PM	Relapsed Follicular Lymphoma	Nathan H. Fowler, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2:15 PM	<p>Debate: Do We Need Maintenance Anti-CD20 Antibody After RCHOP/R-Chemo for Newly Diagnosed Follicular Lymphoma? Pro</p>	Mathias J. Rummel, MD, PhD	Justus-Liebig University-Hospital, Giessen, Germany
2:30 PM	<p>Debate: Do We Need Maintenance Anti-CD20 Antibody After RCHOP/R-Chemo for Newly Diagnosed Follicular Lymphoma? Con</p>	Massimo Federico, MD	University of Modena and Reggio Emilia, Modena Italy
2:45 PM	Advances in the Treatment of PCNSL	Christopher J. Melani, MD	National Cancer Institute, Bethesda, Maryland, USA
3:00 PM	BREAK		
3:30 PM	How I Treat Double Hit Lymphoma	Kieron M. Dunleavy, MD	George Washington University Cancer Center, Washington, DC, USA
3:45 PM	<p>Oral Abstract Presentations NHL 049: Second Primary Malignancies in T-cell Neoplasm Survivors: An United States Population-Based Analysis</p>	Anuhya Kommalapati, MD	University of South Carolina School of Medicine, Columbia, South Carolina, USA
3:55 PM	<p>NHL 088: Angiogenesis' Related Polymorphism Emerges as Prognostic Marker in de Novo Large B-cell Lymphoma Patients</p>	Angelo Brito, MD	University of Campinas, Campinas, São Paulo, Brazil
4:05 PM	<p>NHL 102: Axicabtagene Ciloleucel in Patients With Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1</p>	Sattva Neelapu, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

4:15 PM	NHL 122: Durability of Response in Patients With Refractory Large B Cell Lymphoma Treated With Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1	Sattva Neelapu, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4:25 PM	NHL: Next Questions	Anas Younes, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
4:40 PM	ADJOURN		

INDUSTRY EXPERT SESSION

4:40 PM	Industry Expert Session: Hors d'Oeuvres and Drinks Redefining Approaches in the Early-Line Treatment of Multiple Myeloma <i>This activity is supported by Janssen</i>	William Velasquez, MD	Memorial Hermann, Houston, Texas, USA
---------	--	-----------------------	---------------------------------------

INDUSTRY EXPERT SESSION

5:45 PM	Industry Expert Session: Dinner ADCETRIS® and AVD: New Clinical Review <i>This activity is supported by Seattle Genetics</i>	Hillard M. Lazarus, MD, FACP	Case Western Reserve University, Cleveland, Ohio
---------	---	------------------------------	--

SATURDAY, SEPTEMBER 15, 2018

DATE/TIME	TOPIC/EVENT	SPEAKER	AFFILIATION
6:30 AM	ISS Registration and Breakfast		
7:00 AM	Independent Satellite Symposium Integrating BTK Inhibitors Into the Management of B-Cell Malignancies: How Is Evidence Driving Patient Care? Michael Wang, MD and Michael J. Keating, MB BS <i>This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. This activity is supported by an independent educational grant from AstraZeneca. For more information and to register for this independent symposium, go to www.peerview.com/bcellnhl.</i>		

BREAKFAST WITH THE EXPERT VIII

7:00 AM	Future of Molecular Monitoring	Simona Soverini, PhD	University of Bologna, Bologna, Italy
---------	--------------------------------	----------------------	---------------------------------------

SESSION IX: CHRONIC LYMPHOCYTIC LEUKEMIA

Session Chairs: Florence Cymbalista and Michael Keating

8:00 AM	CLL: State of the Art Update	Florence Cymbalista, MD, PhD	Hôpital Avicenne, Bobigny, France
8:15 AM	Genomic Landscape of CLL	Anna Schuh, MD, PhD, MRCP, FRCPath	University of Oxford, Oxford, United Kingdom
8:30 AM	Evolving First-line Treatment for Patients with CLL	Nitin Jain, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:45 AM	Debate: CIT is Over? Yes	Philip Thompson, MB, BS	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:00 AM	Debate: CIT is Over? No	Barbara F. Eichhorst, MD	University of Cologne, Cologne, Germany
9:15 AM	Sequencing of Targeted Therapy	Anthony R. Mato, MD, MSCE	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
9:30 AM	Oral Abstract Presentations CLL 116: Risk of infection with Ibrutinib in Patients with Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials	Somedeb Ball, MD	Texas Tech University Health Sciences Center, Lubbock, Texas, USA
9:40 AM	CLL 200: LOXO-305, A Next Generation Reversible BTK Inhibitor, For Overcoming Acquired Resistance to Irreversible BTK Inhibitors	Barbara Brandhuber, PhD	Loxo Oncology, Boulder, Colorado, USA
9:50 AM	CLL: Next Questions	Florencia Cymbalista, MD, PhD	Hôpital Avicenne, Bobigny, France

BREAK

SESSION X: RESEARCH TOPICS

Session Chairs: Renier Brentjens and Ralf Dressel

10:35 AM	Animal Models of Bone Marrow Transplantation - Advantages and Limitations Exemplified Through the MICA/NKG2D Signaling Pathway	Prof. Dr. med. Ralf Dressel	Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany
10:50 AM	Single-cell Analysis to Assess Cross-Priming of Tumor-Reactive T Cells	Joshua Brody, MD	Mount Sinai School of Medicine, New York, New York, USA
11:05 AM	Lung Injury After Allogeneic Hematopoietic Cell Transplantation	Gerhard C. Hildebrandt, MD, FACP	University of Kentucky, Lexington, Kentucky, USA
11:20 AM	Targeting Leukemia Metabolism	Jing Chen, PhD	Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

Program of Events**SOHO 2018****Oral Abstract Presentation**

11:35 AM	RES 166: Differences in IGHV Gene Usage and Stereotypic Receptors in CLL and SMZL	Hunan Julhakyan, MD, PhD	National Research Center for Hematology, Moscow, Russia
11:45 AM	The Role of Microbiome in Allogenic Stem Cell Transplant	Marcel R. M. van den Brink, MD, PhD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
12:00 PM	Novel CAR T Cells for Multiple Myeloma	Eric Smith, MD, PhD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
12:15 PM	Hematopoietic Stem Cell Rejuvenation: Aging Alters the Epigenetic Asymmetry of Stem Cell Divisions	Maria Carolina Florian, PhD	Ulm University, Ulm, Germany
12:30 PM	POSTER AWARDS, DRAWING AND CLOSING REMARKS		
12:45 PM	ADJOURN		